logo

For the Inventor, By the Inventor

Heidelberg, Germany

Apogenix Ag

Calculating rank
USPTO Granted Patents = 27

% Expired Patents = 44.4



Trademarks = 5

Forward Citations = 39

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Christian Gieffers (26 out of 37 patents)

silverMedal Oliver Hill (25 out of 35 patents)

bronzeMedal Meinolf Thiemann (25 out of 38 patents)

4.  Tim Schnyder (9 out of 9 patents)

5.  Harald Fricke (4 out of 4 patents)

6.  Jaromir Sykora (3 out of 3 patents)

7.  Christian Merz (2 out of 2 patents)

8.  Marcus Branschädel (2 out of 5 patents)

9.  Marcus Branschaedel (2 out of 3 patents)

10.  Claudia Kunz (1 out of 15 patents)

11.  Michaela Fontenay (1 out of 6 patents)

12.  Susan E Lappe (1 out of 4 patents)

13.  Fritz G Buchanan (1 out of 1 patent)

14.  Darren C Phillips (1 out of 1 patent)

15.  Henning Walczak (5 patents)


Core Competencies:
Single-Chain Fusion Polypeptides
CD95L Antibody
Tumor Necrosis Factor Receptor
Receptor Agonist Proteins
Nucleic Acids
Diagnostic Antibodies
Collectin Fusion Proteins
Signal Peptides
MDS Treatment
Fusion Proteins
Trimers
CD27 Ligand

27 patents:

1. 11214605 - Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells (2022-01-04),
2. 11149075 - Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins (2021-10-19),
3. 11014991 - Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody (2021-05-25),
4. 10870688 - Single-chain CD137-receptor agonist proteins (2020-12-22),
5. 10844108 - Single-chain CD27-receptor agonist proteins (2020-11-24),
6. 10793616 - Single-chain CD40-receptor agonist proteins (2020-10-06),
7. 10683338 - Single-chain TL1A receptor agonist proteins (2020-06-16),
8. 10683332 - Single-chain light receptor agonist proteins (2020-06-16),
9. 10640543 - CD27 ligand (CD27L) single-chain fusion polypeptides (2020-05-05),
10. 10533043 - Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins (2020-01-14),
11. 10519217 - CD27L collectin fusion proteins and encoding nucleic acids (2019-12-31),
12. 10519208 - CD40L single-chain fusion polypeptides and encoding nucleic acids (2019-12-31),
13. 10428154 - Monoclonal anti-CD95L antibody (2019-10-01),
14. 10370441 - Nucleic acids encoding artificial signal peptides and methods of production thereof (2019-08-06),
15. 10266600 - Diagnostic anti-CD95L antibody (2019-04-23),
Company Overview
Apogenix AG is a biopharmaceutical company based in Heidelberg, Germany, specializing in the development of innovative therapeutics for cancer treatment. The company focuses on harnessing the power of its proprietary technology platform to create targeted immunotherapies that modulate the immune system. Apogenix is dedicated to advancing its research in the field of oncology, aiming to improve patient outcomes through novel treatment options that address unmet medical needs in cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

27 Patents

#14 in Heidelberg

#1,742 in Germany

#24,046 in the World

Heidelberg, DE
Heidelberg, Germany

Apogenix Ag

Forward Citations = 39

14 inventors:

goldMedal Christian Gieffers (26 out of 37 patents)

silverMedal Oliver Hill (25 out of 35 patents)

bronzeMedal Meinolf Thiemann (25 out of 38 patents)

4.  Tim Schnyder (9 out of 9 patents)

5.  Harald Fricke (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Apogenix Ag. Retrieved from https://idiyas.com/company/apogenix-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…